ENGOT-EN6/NSGO-RUBY
Trial Description:
A Phase 3, randomized, double-blind, multicenter study of Dostarlimab (TSR-042) plus Carboplatin-Paclitaxel versus Placebo plus Carboplatin-Paclitaxel in patients with reurrent or primary advanced endometrial cancer
Lead Cooperative Group:
Disease Site:
Endometrial
Trial Status:
Recruitment Pending
Contact person: